Cargando…
Cancer stem cell drugs target K-ras signaling in a stemness context
Cancer stem cells (CSCs) are considered to be responsible for treatment relapse and have therefore become a major target in cancer research. Salinomycin is the most established CSC inhibitor. However, its primary mechanistic target is still unclear, impeding the discovery of compounds with similar a...
Autores principales: | Najumudeen, A K, Jaiswal, A, Lectez, B, Oetken-Lindholm, C, Guzmán, C, Siljamäki, E, Posada, I M D, Lacey, E, Aittokallio, T, Abankwa, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057041/ https://www.ncbi.nlm.nih.gov/pubmed/26973241 http://dx.doi.org/10.1038/onc.2016.59 |
Ejemplares similares
-
Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner
por: Posada, Itziar M.D., et al.
Publicado: (2017) -
Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1
por: Posada, Itziar M. D., et al.
Publicado: (2017) -
ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold
por: Posada, Itziar M. D., et al.
Publicado: (2016) -
Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling
por: Siddiqui, Farid Ahmad, et al.
Publicado: (2021) -
Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation
por: Šolman, Maja, et al.
Publicado: (2015)